Natural Killer Cells Therapeutics Market Size, Key Players Analysis, Competitive Scenario and Development Status 2021-2030| Acepodia Inc., Affimed GmbH, Artiva Biotherapeutics Inc., Cytovia Therapeutics

Global Natural Killer Cells Therapeutics Market Report by Absolute Markets Insights is a meticulously undertaken study. Experts with proven credentials and a high standing within the research fraternity have presented an in-depth analysis of the subject matter, bringing to bear their unparalleled domain knowledge and vast research experience. They offer some penetrating insights into the complex world of Natural Killer Cells Therapeutics Market Industry. Their sweeping overview, comprehensive analyses, precise definitions, clear classifications, and expert opinions on applications, make this report nothing short of brilliant in its presentation and style.

Natural killer (NK) cells, also known as large granular lymphocytes (LGL), are defined as a type of cytotoxic lymphocyte which is critical to the innate immune system in the human body. NK cells belong to the innate lymphoid cells (ILC) which is a rapidly expanding family in the world of biological cells. They represent 5% to 20% of all circulating lymphocytes in humans. They are useful in the treatment of various types of cancers. Hence, many scientists are conducting research to explore new possible uses of NK cells regarding medical treatment. Increase in medical research in the field of natural killer cells therapeutics is profusely driving the growth of Global Natural Killer Cells Therapeutics Market. In recent years, scientists have started to re-engineer T cells to attack evasive tumors and creating the first chimeric antigen receptor (CAR)-T treatments. Many researchers have also started to seriously explore how to do the same with natural killers. Experiments have been carried out by attaching CARs for CD19 to natural killer cells. With the cells being injected into patients with either non-Hodgkin lymphoma or chronic lymphocytic leukemia, so far majority cases have been turned out to be positive as the tumors of majority patients vanished.

Global Natural Killer Cells Therapeutics Market to Grow at 17% CAGR during 2021-2030, Owing to Increasing Investments towards Enhancing Effectiveness of Natural Killer Cells Therapeutics, Reports Absolute Markets Insights

Request for Sample Copy of This Report: https://www.absolutemarketsinsights.com/request_sample.php?id=862

Investments towards enhancing effectiveness of natural killer cells therapeutics showcases positive growth opportunities for the global natural killer cells therapeutics market over the forecast period. CAR T is a new cell-based cancer immunotherapy. To provide a therapeutic anti­cancer effect, NK cells do not need any kind of antigen-specific priming. The efficacy of CAR modified peripheral blood natural killer cells being used for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia has been proven. Due to the spread of the China-originated coronavirus disease 2019 (COVID-19) which is also known as SARS-CoV-2 (SARS stands for Severe Acute Respiratory Syndrome), the immunological characteristics of COVID-19 are being researched. In some countries, NK cells are being experimented with the methods of lymphopenia to minimize the damage that coronavirus can cause to patients. A research to find a method using natural killer cells therapeutics for COVID treatment can be a big opportunity for the global natural killer cells therapeutics market.

Enquiry Before Buying this Report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=862

Key Findings of the Report:
• The global natural killer cells therapeutics market is anticipated to reach US$ 6317.20 Mn by 2030 growing at a CAGR of 17% during the forecast period (2021-2030).
• The NK cell therapies category in the global natural killer cells therapeutics market held the larger market share in 2020. NK cells are capable of recognizing a wide range of ligands. Each of these can induce a cytolytic response. NK cells can also be easily isolated and expanded ex vivo. This allows for their use in adoptive or autologous cell therapies.
• Cancer emerged as a dominant category under therapeutic indication in the global natural killer cells therapeutics market. The potent innate immune system effectors for cancer treatment can be harnessed from natural killer cells therapeutics. For example, in anticancer therapy, the checkpoint immunotherapy targets inhibitory receptors of T cells and reverses their functional blocking.
• The peripheral blood segment held the largest share in the global natural killer cells therapeutics market in 2020. A medical technique called leukapheresis has made it possible to harvest cells directly from the peripheral blood of a donor. In this technique, immune cells are separated out from red blood cells. Peripheral blood mononuclear cells (PBMCs) are the most common source of NK cells. It is possible to collect PBMCs through apheresis or a specific gravity centrifugal method such as Ficoll separation.
• Considering the end users segment, the hospitals & clinics segment occupied the largest market share in 2020 and is also anticipated to witness highest CAGR during the forecast period.
• In 2020, North America was the biggest regional market in the global natural killer cells therapeutics market due to advanced medical research that was carried out in the medical institutions located in USA and Canada. Developed medical sector, presence of key market players, and technological advancement supporting the medical research, are some of the prominent factors contributing to the market growth in this region.
• Some of the major players operating in the global natural killer cells therapeutics market are Acepodia Inc., Affimed GmbH, Artiva Biotherapeutics Inc., Cytovia Therapeutics, Dragonfly Therapeutics, EMERCell, Fate Therapeutics, Fortress Biotech Inc., Glycostem, ImmunityBio Inc., Innate Pharma S.A., Kiadis Pharma, Nkarta Inc., NKGen Biotech, NKMAX Co. Ltd., and ONK Therapeutics Limited amongst others.

Request for Customization:
https://www.absolutemarketsinsights.com/request_for_customization.php?id=862

Global Natural Killer Cells Therapeutics Market Segmentation:

By Type
• NK Cell Therapies
• Antibody Directed NK Cell Therapies
By Therapeutic Indication
• Cancer
• Viral Infections
• Autoimmune Diseases
• Neurodegenerative Diseases
• Others
By Source
• Peripheral Blood
• Umbilical Cord Blood
• Induced Pluripotent Natural killer cells therapeutics (iPSC)
• Others
By End Users
• Hospitals & Clinics
• Research Institutes
• Others
By Region:
• North America [U.S., Canada, Mexico]
• Europe [Germany, UK, France, Italy, Rest of Europe]
• Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
• South America [Brazil, Argentina, Rest of Latin America]
• Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

Get Full Information of this premium report: https://www.absolutemarketsinsights.com/reports/Natural-Killer-Cells-Therapeutics-Market-2021---2029-862

Contact Us:

Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.
From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

This release was published on openPR.